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 ABSTRACT 
Objectives:  To develop and validate a predictive MRI activity score for 
ileocolonic CD activity based on both subjective and semi-automatic MRI 
features. 
Materials and Methods: An MRI activity score (the "VIGOR" score) was 
developed from 27 validated MR enterography datasets including subjective 
radiologist observation of mural T2 signal and semi-automatic measurements 
of bowel wall thickness, excess volume and dynamic contrast enhancement 
(initial slope of increase; ISI). A second, subjective score was developed 
based on only radiologist observations. For validation, two observers applied 
both scores and three existing scores to a prospective dataset of 106 patients 
(59 female, median age 33) with known CD, using the endoscopic Crohn's 
Disease Endoscopic Index of Severity (CDEIS) as a reference standard.  
Results: The VIGOR score (17.1*ISI + 0.2*excess volume + 2.3*mural T2), 
and other activity scores all had comparable correlation to CDEIS (Ob1/2, 
r=0.58/0.59, 0.34–0.40/0.43–0.51, respectively). The VIGOR score, however, 
improved interobserver agreement compared to the other activity scores 
(ICC=0.81 vs. 0.44–0.59). Diagnostic accuracy of 80%–81% was seen for the 
VIGOR score, similar to the other scores. 
Conclusions:  The VIGOR score achieves comparable accuracy to 
conventional MRI activity scores, but with significantly improved 
reproducibility, favouring its use for disease monitoring and therapy 
evaluation. 
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 INTRODUCTION 
 
Crohn's disease is an inflammatory bowel disease, which can present 
throughout the gastrointestinal tract, particularly affecting the small bowel and 
colon. Magnetic resonance imaging (MRI) is increasingly used for diagnosis 
and phenotyping of Crohn's disease, because it is safe, non-invasive and has 
high accuracy for evaluating enteric disease and extramural complications 1. 
MRI features such as wall thickness and T1/T2 bowel wall signal have been 
validated as biomarkers of Crohn's disease activity, demonstrating good 
correlation with endoscopic and histopathologic grading of inflammation 2–4.  
Recent years have seen several MRI disease activity scores being developed 
and externally validated, combining multiple MRI features to predict overall 
disease activity 3–6. These scores are gradually disseminating into clinical 
practice, although at present they are predominantly employed as research 
tools. The Magnetic Resonance Index of Activity (MaRIA), for example, has 
been developed using the Crohn's Disease Endoscopic Index of Severity 
(CDEIS) as a reference standard. The MaRIA is based on quantitative 
measurement of relative bowel wall contrast enhancement (RCE) along with 
subjective evaluation of mural ulceration and abnormal T2 signal 3. Other 
indices, such as the London score and Crohn's Disease MRI Index (CDMI) 
rely on qualitative grading of various features by reporting radiologists 4,6. 
Such activity scores can be applied to individual bowel segments, as well as 
to the patient as a whole, as both are important to clinical management. 
Before MRI scores can be widely adopted for evaluating disease activity and 
therapeutic monitoring, high accuracy across the spectrum of disease 
severity, and good reproducibility between radiologists must be proven. The 
 current literature, however, reports variable reproducibility for many features 
used in MRI activity scores 6,7.  
 
One potential solution to the current limitations of MRI activity scoring is to 
incorporate novel software solutions, which can automatically extract relevant 
features from MRI data. Such software could reduce both interobserver 
variability as well as the risk of observer bias inherent to subjective evaluation 
8. New MRI image processing methods are available, which give semi-
automatic measurements of bowel wall thickness, providing superior 
reproducibility over manual measurement 9. Further techniques have been 
developed which automatically extract perfusion parameters from motion 
corrected free-breathing dynamic contrast enhanced (DCE)-MRI 10. While 
several studies have shown the potential of semi-automatic MRI assessment 
of Crohn's disease 9–11, none of those have examined clinical practicability, 
nor validated their results using a large, independent cohort. 
 
We hypothesize that a scoring system combining semi-automatic software 
measurements with conventional subjective radiologist scoring of MRI 
features can improve accuracy and reproducibility in comparison to existing 
MRI scores. Accordingly, our aim was to develop and validate a predictive 
MRI score for ileocolonic CD activity incorporating novel software assisted 
semi-automatic measurement of MRI features using an ileocolonoscopic 
standard of reference, and to compare its performance with existing MRI 
activity scores.  
 
 MATERIALS AND METHODS 
The study was divided in two phases. Firstly, a detailed modeling process was 
undertaken to derive two new MRI activity scores. Secondly, these new 
scores were validated and compared with existing scores regarding accuracy 
for diagnosis and grading of disease, and score reproducibility. Ethical 
permission was obtained from both institutions’ medical ethics committee and 
written informed consent was obtained from all patients. 
 
Phase 1 - Model development 
The modeling process employed a previously described cohort of 27 patients 
with known Crohn's disease 6. The first developed score specifically 
incorporated semi-automatic measurements of bowel wall thickness and 
enhancement (described in more detail in phase 2 below) and was termed the 
“VIGOR score”. The second score incorporated only the best performing 
combination of a number of subjective evaluations made by radiologists 
(termed the “subjective score”). A full description of the model development is 
given in Appendix A. 
 
Phase 2 - Prospective activity score testing and model comparison  
The validation and comparison of the newly developed and existing activity 
scores was performed using an independent prospective cohort. Between 
October 2011 and September 2014, consecutive patients ≥ 18 years with 
suspected or known Crohn's disease and scheduled for ileocolonoscopy were 
recruited from two European tertiary referral centres for inflammatory bowel 
disease (1. Academic Medical Center (AMC), Amsterdam, the Netherlands, 
 and 2. University College London Hospital (UCLH), London, United Kingdom). 
All included patients underwent MRI and ileocolonoscopy within two weeks. 
The Harvey-Bradshaw Index (HBI) was collected at the time of MRI 12.  
Patient exclusion criteria were contraindications to MRI (e.g. pacemakers, 
claustrophobia), a final diagnosis other than Crohn's disease, failure to 
comply with the oral contrast protocol, >2 weeks between MRI and 
ileocolonoscopy, and incomplete MRI protocol (e.g. missing sequences or 
incomplete imaging) or insufficient bowel cleansing precluding accurate 
mucosal assessment, as determined by the endoscopist. 
 
Reference standard 
Ileocolonoscopy was performed within two weeks of MRI using a standard 
endoscope (model CF-160L, Olympus) by either a gastroenterologist or a 
senior resident in gastroenterology under direct supervision of a 
gastroenterologist. The endoscopist applied the CDEIS to evaluate 
endoscopic disease 13. The endoscopist was blinded to findings on MRI, 
except for cases where a balloon-dilatation procedure was indicated. In these 
cases, the length of stenosis on MRI was used to determine the feasibility of 
balloon-dilatation.  
 
MRI protocol  
Patients fasted for at least 4 hours before the examination and were 
instructed to drink a total of 2400 mL 2.5% Mannitol solution (Baxter, Utrecht, 
the Netherlands) split in two doses: 800 mL (3 hours prior to MRI) and 1600 
mL (1 hour prior to MRI), to achieve distension of both colonic and small 
 bowel segments. MRI examinations were performed on a 3.0 T MRI unit 
(Ingenia/Achieva; Philips, Best, the Netherlands) in the supine position using 
a phased-array body coil. The MRI protocol used in both centres is outlined in 
Appendix A. DCE images were mutually aligned using the registration method 
described by Li et al. 10,14. 
 
Image analysis 
MRI examinations were evaluated using online viewer software (3Dnet Suite, 
Biotronics3D, London, UK) by two pairs of observers (Ob1: C.Y.N, J.S.; Ob2. 
D.P, S.T.) with extensive experience in MR enterography (>1100, >800, >500 
and >1500 examinations, respectively). The first pair of observers was from 
AMC, the second pair from UCLH. Each MRI dataset was independently 
evaluated by one observer from both pairs, resulting in two evaluations per 
dataset. Observers were blinded to each other’s findings and clinical data.  
Scan quality, luminal distension and MRI features from three existing 
validated MRI disease activity scores (MaRIA, London and CDMI scores) 
were evaluated 3,4. Details of image analysis and score calculation can be 
found in Appendix A. 
 
Semi-automatic measurements 
Using our online viewer software, the bowel’s centreline was indicated on MRI 
individually by each observer by manually placing a number of widely spaced 
points within the lumen of the bowel on the post-contrast coronal T1-weighted 
sequence (Figure 1). If a bowel segment harboured active disease (defined as 
a >0 score on at least one subjective MRI feature), the centreline was placed 
 across the affected part. In the absence of disease activity it was placed in a 
representative part of the bowel segment. Subsequently, the volume of the 
bowel wall was automatically delineated using the segmentation method 
available in the our online imaging viewers' post-processing environment 9. 
From this delineation the following features were automatically obtained: 
maximum bowel wall thickness (mm), mean bowel wall thickness (mm) and 
excess bowel wall volume (mm3) (Appendix A). Additionally, each delineation 
was used as a 3D region of interest on DCE images to extract the initial slope 
of increase (ISI) of the enhancement curve (the initial slope of increase 
corresponds to the mathematically defined A1 feature in the reference paper) 
10.  
 
Validation of MRI activity scores and Statistical analysis 
Assessment of the validity of segmental scores in Crohn's disease patients 
can be challenging due to the high numbers of healthy segments relative to 
the small number of actively diseased segments (which may skew and inflate 
agreement statistics). For this reason, we validated the newly developed 
scores in two ways.  
 
The primary validation was restricted to segments with active disease on MRI 
from the full prospective cohort. The applied definition of active disease (>0 
score on at least one subjective MRI feature) was chosen as a low threshold 
to obtain the highest yield of segments in this primary analysis without 
creating a selection bias to one of the activity scores. The selection was not 
based on endoscopic disease activity, as this would require unblinding of 
 endoscopic information to the radiologist. Grading accuracy was evaluated by 
correlating segmental activity scores for each observer individually against the 
segmental CDEIS. Segments with missing model features (i.e. non-evaluable 
subjective features or failure to generate semi-automatic features) were 
excluded, so that all activity scores were available in each segment. 
Additionally, interobserver agreement was calculated for all overlapping active 
segments (i.e. deemed active by both observers) using the ICC for absolute 
agreement.  
The secondary validation concerned the same evaluation of grading accuracy 
and interobserver agreement on all segments (i.e. active and 
healthy/remission) from the subset of 50 patients. In these data the 
distribution of disease forms a skewed distribution of segmental score values, 
violating the assumption of normality for the intraclass correlation coefficient 
(ICC), the standard measure for interobserver agreement in continuous data. 
Accordingly, we applied both the conventional ICC and a modified, non-
parametric ICC by Rothery et al. for a comprehensive evaluation of 
interobserver agreement 15. This measure has been used in several studies 
16,17. The subset was determined by random number generation from within 
the set of complete studies to minimize risk of selection bias, while a sample 
size calculation was performed using previous MRI performance data 
(Appendix A) 6.  
In both analyses, the developed scores from phase one were compared to 
three existing MRI activity scores (MaRIA, London and CDMI scores). 
Diagnostic accuracy and per-patient analysis were performed using the 
 subset of 50 patients, as detailed in Appendix A.  
Spearman rank correlations were interpreted as follows: 0–0.20, very weak; 
≥0.20–0.40, weak; ≥0.40–0.60, moderately; ≥0.60–0.80, strong; ≥0.80–1.00, 
very strong. Correlation coefficients were then compared using the Steiger Z-
test for (non-)overlapping, dependent correlations 18. Interobserver agreement 
(ICC or non-parametric ICC) was evaluated using the following criteria for 
interpretation: 0–0.20, poor; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, 
good; 0.81–1.00, very good 19. Diagnostic accuracy values were compared 
using McNemar's test. We considered a P-value of < 0.05 to indicate a 
statistically significant difference. Model development and validation were 
implemented with R Statistical language (v3.1.2, Vienna, Austria) 20. 
Descriptive statistics were analyzed using SPSS 22 for Mac (SPSS, Chicago, 
USA). 
 
RESULTS 
Phase 1 - Model development 
The developed VIGOR and subjective models were: 
VIGOR score =  17.1 ×  ISI + 0.2 ×  excess volume + 2.3 ×  mural T2 
Subjective score 
=  0.03 ×  RCE +  0.9 ×  mural thickness (mm) +  3 ×  mural T2  
A VIGOR score of ≥ 5.6 was determined via ROC analysis as the optimal cut-
off value for active disease (CDEIS ≥3). For the subjective score, the optimal 
 cut-off value for active disease was ≥ 4.8. Details of the development cohorts' 
segmental exclusions are shown in Appendix B. 
 
Phase 2 - Prospective activity score testing and comparison 
After exclusions (Figure 2), the final prospective study cohort consisted of 106 
patients with known Crohn's disease, for which demographics and clinical 
characteristics are provided in Table 1. Characteristics of the 50 patients 
randomly determined subset used for evaluation of diagnostic accuracy and 
per-patient scores can be found in Appendix B. One patient experienced 
abdominal pain and cramping after the MRI examination, which were 
successfully treated with simple analgesia.  
 
Mean scan image quality (0–3) was 2.2 (SD: 0.6). Mean distension values (0–
4) for terminal ileum and colon were both 3.4 (SD: 0.7). Within evaluable 
segments (evaluable on MRI by the radiologist and at endoscopic intubation), 
Ob1 and Ob2 identified 88 and 95 segments with active disease on MRI, 
respectively. In the subset of 50 patients, a total of 230 and 229 segments 
(both active and healthy/remission) were evaluable for Ob1 and Ob2, 
respectively. 
 
In active segments (>0 score on at least one subjective feature), the VIGOR 
score could be calculated in 83% (73/88) of segments for Ob1 and in 73% 
(69/95) for Ob2. In the 50-patients subset, the VIGOR score could be applied 
to 73% (167/230) of segments for Ob1. Exclusion of rectum segments from 
the analysis increased this rate to 87% (161/186). For Ob2, the VIGOR score 
 was applied to 70% (161/229) of segments, which increased to 82% 
(153/187) after exclusion of rectum segments. Details on inclusion of bowel 
segments can be found in Table 2.  
 
Model validation and comparison 
Correlations to CDEIS for each observer pair and interobserver agreement 
are presented in Table 3. In active segments, the VIGOR score showed 
moderate correlations to CDEIS (Ob1/2: r=0.58/0.59). Weak-to-moderate 
correlations to CDEIS were seen for the subjective score (r=0.39/0.51), 
MaRIA (r=0.40/0.43), the London score (r=0.38/0.45) and the CDMI 
(r=0.34/0.48). Significant differences were seen for Ob1 between the VIGOR 
score and the subjective score (p=0.04), the London score (p=0.03), the 
CDMI (p=0.01), but not the MaRIA (p=0.05). For Ob2, no significant 
differences were seen (p=0.10–0.35). The VIGOR score showed very good 
interobserver agreement in active segments (ICC=0.81), compared to fair 
agreement for other activity scores (ICC=0.44–0.59). Interobserver scatter 
plots for all scores can be found in Appendix B, which show visually similar 
agreement for the analyses on the active segments of the full dataset and all 
segments of the subset, while in the latter all scores show narrow clustering 
(i.e. high reproducibility) of healthy segments.  
 
In the subset of 50 patients including all segments (active and 
healthy/remission), the VIGOR score showed moderate correlation to CDEIS 
(Ob1/2, r=0.57/0.53) for segmental disease activity, while the correlations for 
the other activity scores ranged between 0.50–0.61 for Ob1 and between 
 0.53–0.64 for Ob2. No significant differences were seen between the VIGOR 
score and other activity scores for Ob1 (p=0.2–0.6). For Ob2, the CDMI and 
London score showed significantly higher correlation to CDEIS compared to 
the other activity scores (p=0.02–0.03). Conventional ICC values for active 
segments and all segments and non-parametric ICC values for all segments 
from the subset of 50 patients are shown in Table 4. It can be observed that 
the conventional ICC values for all segments were evidently higher compared 
to ICC values in active segments and the non-parametric ICC, especially for 
the subjective and existing activity scores. Using the non-parametric ICC, the 
VIGOR score showed very good agreement of (ICC=0.89), compared to poor-
to-fair agreement for other activity scores (ICC=0.33-0.56), which was a 
significant difference (p<0.001).  
 
Diagnostic accuracy  
The diagnostic accuracy for all MRI scores are presented in Table 5. No 
significant differences in diagnostic accuracy were seen (p>0.05), except for 
the subjective scores' significantly lower accuracy for Ob1 compared to other 
activity scores (p<0.01). 
 
Per-patient activity scores in the subset showed moderate correlations to 
CDEIS for the VIGOR score (Ob1/2, r=0.53/0.54), subjective score 
(r=0.60/0.57), MaRIA (r=0.58/0.51), London score (r=0.58/0.56) and CDMI 
(r=0.53/0.59). There were no significant differences between any pair of 
activity scores (p>0.05). Per-patient scores showed similar (conventional) 
ICC's for the VIGOR score (0.77, 95%CI: 0.62–0.86), subjective score (0.71, 
 95%CI: 0.51–0.83), MaRIA (0.75, 95%CI: 0.54–0.87), London score (0.74, 
95%CI: 0.57–0.84) and CDMI (0.79, 95%CI: 0.65–0.88). 
 
 
DISCUSSION 
In this development and validation study, evidence is provided for a new MRI 
CD activity scoring system, the “VIGOR score”, incorporating both subjective 
observations and semi-automatic features. The VIGOR score achieved 
improved segmental reproducibility compared to existing activity scores, such 
as the MaRIA, London score and CDMI. The VIGOR score showed similar 
correlation with the endoscopic standard of reference and diagnostic accuracy 
compared to other activity scores. The VIGOR score also showed superior 
performance in comparison to a new subjective score, which was developed 
and validated using the same cohorts. When considering the per-patient 
VIGOR score, correlation with CDEIS remained moderate and interobserver 
agreement remained very good. In contrast to the segmental analyses, per-
patient scores showed high agreement for all activity scores. This difference 
can be explained through the high reproducibility of all activity scores in 
healthy segments (Appendix B), which considerably influences the per-patient 
scores' agreement due to their high prevalence. 
MRI activity scores are currently being investigated for use as outcome 
measures in clinical trials, with some success 21,22. Clearly, for use in 
multicenter studies, a high level of reproducibility between readers is 
imperative. Therapeutic management requires high reproducibility in both 
segmental and patient scores, as these serve different purposes in guidance 
 and evaluation of surgical and medical therapy. Many Crohn’s disease 
patients have limited segmental disease (usually ileocecal disease), such that 
segmental reproducibility for disease activity is paramount. Conversely, a 
more global overview is important in those with multi-focal disease. Our study 
reports very encouraging performance characteristics for the newly developed 
semi-automatic score: correlation with CDEIS is at least as good as existing 
scores, yet only the VIGOR score maintained high reproducibility in both per-
segment and per-patient analyses. The next stage of development should 
now investigate the ability of the VIGOR score to monitor therapy via 
longitudinal studies, similar to work reported by Ordas et al. evaluating the 
MaRIA 22.  
Compared to existing evaluations of MRI activity scores, we found relatively 
low correlations with CDEIS 5,6,22. We hypothesize that this is caused by the 
disease spectrum in our prospective cohort, with relatively high prevalence of 
mild disease. This is confirmed by the median CDEIS, CRP and HBI values 
from our prospective cohort (Table 1 and Appendix B), which are much lower 
than those in previous studies 3,4. Furthermore, our results are accordant with 
previous results from our two inclusion centres 4,6.  
The presence of mural ulceration has been reported as a useful sign of 
activity and is incorporated in the MaRIA score. However, we did not include 
evaluation of ulceration in our model development as data suggests that it is 
highly reader dependent 6. Furthermore, all five MRI scores (four of which did 
not include ulceration) achieved similar correlation to CDEIS and diagnostic 
accuracy for active segments.  
 Our primary analysis was limited to active segments as large numbers of 
normal segments can skew agreement statistics and result in over-optimistic 
estimates. The skewing of data is confirmed by our results; increased ICC's 
were seen for subjective activity scores in the inclusive analyses of all 
segments, while no improved agreement is observed visually in the 
corresponding scatter plots or when using the non-parametric ICC.  
Our study has several limitations. The DCE sequence employed in our 
development cohort used a smaller field of view compared to the sequence 
used in the prospective cohort, which limited the amount of ISI data for model 
development. Because the field was positioned on the terminal ileum, the 
excluded segments from the development cohort were mainly colonic and 
rectum segments (81% of exclusions). Exclusions were improved 
considerably in the prospective cohort, although a relatively large number of 
rectum segments were excluded due to being out of the field-of-view on DCE. 
Simultaneously, our results do reveal current limitations of semi-automatic 
features, as measurements in segments with suboptimal preparation were 
limited. Although subjective evaluation is also affected, human interpretation 
remains superior in coping with the effects of suboptimal preparation on mural 
thickness and contrast-enhancement. However, semi-automatic software 
together with MRI sequences continuously undergo improvement and as 
such, an increase in success-rate can be expected. These improvements 
might prove especially beneficial for inexperienced MRI readers. Although all 
readers in our study had extensive experience in MR enterography, future 
research should explore the semi-automatic scores' application by readers of 
different levels of experience. 
 Currently, steps are being taken to further technically optimize the semi-
automatic MRI measurements and to provide full integration in viewer 
software. Clearly, these aspects are essential for clinical applicability, which 
requires easy to use techniques.  
In conclusion, the use of semi-automatic features for assessment of patients 
with CD maintains diagnostic and grading accuracy, while improving 
reproducibility over conventional activity scores. These characteristics make it 
potentially suitable for therapy evaluation and monitoring of disease activity. 
Furthermore, accurate and reproducible MRI scores could improve the 
physician's trust in these scores to make consistent and effective treatment 
decisions.  
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Figure 1  
(A) Placement of centreline points in the lumen of an affected transverse 
colon segment on a coronal contrast-enhanced 3D T1-weighted SPGE image 
with fat saturation. A few centreline points are placed in the middle of the 
lumen in one or more slices. (B) The delineation of the inner and outer bowel 
wall surfaces is visualized by a red line. Presently this is shown on a coronal 
slice, but it can be visualized in a similar way in reconstructed sagittal or 
transversal planes. 
 
Figure 2  
Flow diagram detailing patient in- and exclusions. 
  
 Appendix A: supplemental Methods 
 
Model development 
For development of the scoring systems, an independent cohort was used, 
consisting of 27 patients with known Crohn's disease undergoing MR 
enterography (MRE) and ileocolonoscopy (with segmental CDEIS scoring) 
within four weeks. Prior to MRE, a standardized small bowel preparation was 
used consisting of 4 hours fasting and 1600 mL 2.5% Mannitol solution 
ingested over 1 hour before the scan. This cohort was recruited for a previous 
study 1. Three patients were excluded from the original cohort, because no 
informed consent could be obtained for future research.  
Scans from the development cohort were all individually evaluated by four 
observers (C.Y.N., D.P., J.S., J.M.) resulting in four evaluations per dataset 1. 
All readers were unaware of the findings at the initial reading (> 1 year before 
study reading for all cases) and the findings from ileocolonoscopy, but were 
aware of patients' surgical history. MRI examinations from were evaluated 
using online viewer software (3Dnet Suite, Biotronics3D, London, UK). 
Features common to three previously validated MRI activity scores (MaRIA, 
London score and CDMI) were evaluated in all segments of the dataset and 
included in the selection process for model development. By reducing the 
number of features to include only the most essential, the potential validity of 
the developed model is increased. The included features comprised three 
categories: 1. mural thickness, 2. contrast enhancement (either subjectively 
graded or quantified using RCE) and 3. T2 mural signal intensity (classified in 
the MaRIA as mural edema) (see Score calculation, Appendix A). Additional 
 features, for example perimural T2 signal and ulceration, were not included as 
they are not common to all MRI activity scores. Semi-automatic 
measurements – maximum and mean bowel wall thickness, excess bowel 
wall volume and the initial slope of increase (ISI) – were calculated for all 
evaluated segments. 
These features have been scored by four radiologists independently 1. All 
samples of the four readers were used for model development, without 
averaging over the readers, since our model was intended to be applied on 
single readers’ outcomes. All generalized linear regression models have been 
trained using R statistical language (v3.1.2) 2.  
Two models were developed based on the previously mentioned three 
categories (mural thickness, contrast enhancement, T2 mural signal). For the 
first model, semi-automatic wall thickness and contrast enhancement 
parameters were included in the development process. For the second model, 
the semi-automatic measurements were excluded, relying only on subjective 
radiologist scores alone for mural thickness, contrast enhancement and T2 
mural signal intensity (See MRI features and grading categories, Appendix A).  
From both the semi-automatic and the subjective models the ‘best’ model was 
selected using a previously described exhaustive search method for 
biomarker discovery 3. In summary, this method evaluated all possible 
combinations of MRI features as candidate models for predicting CDEIS, 
under the above constraint of having at least one feature per category.  
Specifically, the rank correlation to CDEIS of each putative model was 
determined in the retrospective data using a 50-fold bootstrap cross-validation 
 4. Eventually, this procedure delivered two models: the top ranking semi-
automatic model and the top ranking subjective model. These were termed 
the "VIGOR score" and the "subjective score", respectively. 
MRI protocol 
 
  Plane Slice 
thickness  
(mm) 
FOV TR  
(ms) 
TE  
(ms) 
Flip  
angle 
Balanced GE Coronal 5 380x380 2.5 1.25 60 
BTFE dynamic Coronal 10 380x380 2-2.1 1 45 
T2-SSFSE Coronal 4 380x380 628-
660 
60 90 
T2-SSFSE Axial 4 400x400 759 119 90 
T2-w SSFSE fat 
saturation 
Axial 7 380x380 967-
1314 
50 90 
DCE sequence Coronal 2.5 380x380-439 2.9 1.8 15 
3D T1-w SPGE fat 
saturation 
Coronal 2 380x380-459 2.2-2.4 1.0-1.1 10 
3D T1-w SPGE fat 
saturation 
Axial 2 380x380 2.1-2.3 1.0-1.1 10 
BTFE, balanced turbo field-echo; DCE, dynamic contrast enhanced; FOV, field of view; GE, 
gradient echo; SPGE, spoiled gradient-echo; SSFSE, single-shot fast spin echo; TE, echo time; 
TR, repetition time. 
 
The DCE sequence consisted of 300 consecutive volumetric acquisitions at a 
temporal resolution of 1.2 seconds/volume. Intravenous gadolinium contrast 
was administered 60 seconds after the start of the DCE sequence block using 
the standard contrast agent in the participating centres: gadobutrol (Gadovist 
1.0 mmol/L, Bayer Schering Pharma, Berlin, Germany) or gadoterate 
meglumine (Dotarem 0.5 mmol/L, Guerbet, Paris, France). Following the DCE 
series, coronal and axial 3D T1-weighted spoiled gradient-echo (SPGE) 
images were acquired in the delayed phase (approximately 7 minutes after 
contrast injection). To reduce bowel peristalsis, three separate doses of 10 
 mg intravenous butylscopolamine bromide (Buscopan, Boehringer Ingelheim, 
Ingelheim, Germany) were administered during the examination.  
 
 
 
MRI features and grading categories  
 
 
Overall scan quality was graded on a scale from 0 (non-diagnostic images) to 
3 (diagnostic images without artefacts). Subsequently, the following five bowel 
segments were evaluated individually: the terminal ileum (most distal 20 cm of 
the ileum), ascending colon, transverse colon, descending/sigmoid colon and 
rectum. Luminal distension, defined as the percentage of adequately 
distended bowel for diagnostic evaluation, was graded for each segment from 
0 to 4 (< 20%, 20–40%, 40–60%, 60–80%, > 80%).  
MRI Features Grading score 
0 1 2 3 
 
London/CDMI  
Mural thicknessa 1–3 mm > 3–5 mm  > 5–7 mm > 7 mm 
Mural T2 signal Equivalent to 
normal bowel wall 
Minor increase in 
signal-bowel wall 
appears dark grey 
on fat saturated 
images 
Moderate increase 
in signal-bowel wall 
appears light grey 
on fat saturated 
images 
Marked increase in 
signal-bowel wall 
contains areas of 
white high signal 
approaching that of 
luminal content 
Perimural T2 signal Equivalent to 
normal mesentery 
Increase in 
mesenteric signal 
but no fluid 
Small fluid rim (≤ 2 
mm) 
Larger fluid rim (> 2 
mm) 
T1 enhancement Equivalent to 
normal bowel wall 
Minor enhancement 
- bowel wall signal 
greater than normal 
small bowel but 
significantly less 
than nearby 
vascular structures 
Moderate 
enhancement - 
bowel wall signal 
increased but 
somewhat less 
than nearby 
vascular structures 
Marked 
enhancement - 
bowel wall signal 
approaches that of 
nearby vascular 
structures 
 
MaRIA 
  
Mural thickness in mma         
RCE         
Edema Absent Present     
Ulcers Absent Present     
          
a  Measured using electronic calipers 
  
MRI=magnetic resonance imaging, RCE=relative contrast enhancement 
 Score calculation 
Calculation of the London score, the Magnetic Resonance Index of Activity 
(MaRIA) and the relative contrast enhancement (RCE) using bowel wall signal 
intensity (SI) measured in a region of interest: 
  
London score =  1.79 +  1.34 ×  Wall thickness +  0.94 ×  mural T2 signal 
 
CDMI =  Wall thickness +  T1 enhancement +  mural T2 signal 
+  perimural T2 signal   
 
MaRIA =  1.5 ×  Wall thickness (mm)  +  0.02 ×  RCE +  5 ×  oedema +  10 
×  ulceration 
 
RCE  =  
SI postcontrast −  SI precontrast
SI precontrast
 
 
RCE calculation did not include a noise correction term, as was used by 
Rimola et al 5, since inconsistent noise measurements were observed in our 
data, yielding arbitrary RCE values. Signal intensity values were corrected 
using the method described by Chenevert et al 6.  
 
Excess bowel wall volume feature 
The excess bowel wall volume was defined as the volume of the delineated 
region exceeding normal thickness. Normal thickness was calculated as the 
mean automatic thickness of healthy segments (no activity on 
MRI/endoscopy) in the development cohort. 
 Sample size calculation for subset of patients 
Employing an α of 0.05 and a β of 0.20, expected colonic sensitivity of 0.4 and 
prevalence of 0.15, expected terminal ileum specificity of 0.8 and prevalence 
of 0.67, the necessary number of terminal ileum and colonic segments was 
calculated to be 45 and 154 segments, respectively. Anticipating a segment 
exclusion of 10%, a total of 50 patient datasets were required. 
Diagnostic accuracy  
Diagnostic accuracy for segmental disease activity (defined as a CDEIS ≥3 7) 
was assessed by applying segmental MRI scores to all bowel segments of the 
50 randomly selected patients. For evaluation of diagnostic accuracy, 
segmental disease activity on MRI was defined using these predetermined 
cut-off values: MaRIA, ≥7; London score, ≥4.1; CDMI, ≥3 5,8. For the VIGOR 
and subjective scores, the optimal cut-off points for detection of active disease 
were determined using receiver-operating characteristics (ROC) analyses 
performed on the development cohorts' datasets. Sensitivity, specificity, 
positive predictive value, negative predictive value and diagnostic accuracy 
were then calculated for all segments of the prospective subset. 
Per-patient analysis 
For the per-patient analysis, MRI activity scores and global CDEIS in the 
subset were calculated as the sum of segmental scores divided by the 
number of evaluated segments. A stenosis score was added to the per-patient 
CDEIS score if applicable 9. Subsequently, MRI scores (per-patient and per-
segment) were correlated to CDEIS and interobserver agreement was 
determined in all segments using the conventional ICC. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix B: supplemental Results 
 
Development cohorts' segment in- and exclusions 
The retrospective development cohort consisted of 27 known Crohn's disease 
patients (127 segments evaluable by radiologist and endoscopist). Eighteen 
segments (6 colon, 12 rectum) were excluded from the analysis, due to 
severe artefacts (n=4), poor distension (n=7) and fecal residue (n=7). A 
further 42 segments were excluded, as semi-automatic features could not be 
derived in these segments for the following reasons: segment outside the 
DCE field-of-view (33/42), failed DCE registration (8/42) or failed 
segmentation (1/42). Of the 33 segments outside the DCE field-of-view, 91% 
were either colonic (16/33) or rectal (14/33), which was expected for this 
retrospective cohort, as MRI preparation and sequences were not intended for  
colonic evaluation. As such, 67 segments remained. 
 
 
 
 
 
 
 
 
 
 
 
 
 Clinical characteristics of the subset group from the prospective cohort 
    
Total no. of patients 50 
Female, n (%) 29 (58) 
Age at MRI (years), median (IQR) 32 (27–47) 
Previous surgery, n (%) 19 (38) 
Concomitant treatments   
    Anti-TNF antibodies, n (%)  15 (30) 
    Steroids, n. (%) of patients 8 (16) 
    Thiopurines, no. (%)  8 (16) 
    5-ASA, no. (%) of patients 10 (20) 
    Methotrexate, no. (%)  3 (6) 
CRP (mg/L), median (IQR) 4 (2–11) 
HBI, median (IQR) 5 (2–8) 
CDEIS, median (IQR) 4.0 (0.1–7.7) 
Montreal classification   
    Age at diagnosis (years), median (IQR) 22 (19–28) 
    Disease location   
       L1 ileal, n (%) 21 (42) 
       L2 colonic, n (%) 9 (18) 
       L3 ileocolonic, n (%) 20 (40) 
       L4 upper GI tract involvement, n (%) 2 (4) 
   Disease behaviour   
       B1 inflammatory 25 (50) 
       B2 stricturing 16 (32) 
       B3 penetrating 9 (18) 
   Perianal involvement, n (%) 9 (18) 
    
 
5-ASA, 5-acetylsalicylic acid; CDEIS, Crohn's disease Endoscopic Index of 
Severity; CRP, C-reactive protein; GI, gastrointestinal; HBI, Harvey-
Bradshaw Index; IQR, interquartile range; MRE, magnetic resonance 
enterography; TNF, tumour necrosis factor. 
 
 
 
 
 
 
 
 
 
 
 Interobserver scatter plots 
Scatter plots for MRI activity scores between observer 1 (y-axis) and observer 
2 (x-axis). Active (overlapping; active for both observers) segments of the full 
prospective cohort are shown in the left figures, while all (overlapping; 
included for both observers) segments (active and remission) of the 50-patient 
subset are shown in the figures on the right. 
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 Table 1 Clinical characteristics of the prospective cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Total no. of patients 106 
Female, n (%) 59 (56) 
Age at MRI (years), median (IQR) 33 (26–44) 
Previous surgery, n (%) 42 (40) 
Concomitant treatments   
    Anti-TNF antibodies, n (%)  30 (28) 
    Steroids, n. (%) of patients 18 (17) 
    Thiopurines, no. (%)  14 (13) 
    5-ASA, no. (%) of patients 19 (18) 
    Methotrexate, no. (%)  8 (8) 
CRP (mg/L), median (IQR) 5 (1–13) 
HBI, median (IQR) 5 (2–8) 
CDEIS, median (IQR) 3.2 (0.5–6.4) 
Montreal classification   
    Age at diagnosis (years), median (IQR) 22 (17–28) 
    Disease location   
       L1 ileal, n (%) 43 (41) 
       L2 colonic, n (%) 15 (14) 
       L3 ileocolonic, n (%) 48 (45) 
       L4 upper GI tract involvement, n (%) 4 (4) 
   Disease behavior   
       B1 inflammatory 54 (51) 
       B2 stricturing 36 (34) 
       B3 penetrating 16 (15) 
   Perianal involvement, n (%) 23 (22) 
5-ASA, 5-acetylsalicylic acid; CDEIS, Crohn's disease Endoscopic 
Index of Severity; CRP, C-reactive protein; GI, gastrointestinal; 
HBI, Harvey-Bradshaw Index; IQR, interquartile range; MRI, 
magnetic resonance imaging; TNF, tumor necrosis factor. 
 Table 2 Segment inclusions and exclusions 
 
  Active segments Subset (n=50), all  
segments 
Subset (n=50), 
rectum excluded 
  Ob1 Ob2 Ob1 Ob2 Ob1 Ob2 
Total no. of 
segment* 
88 95 230 229 186 187 
              
Inclusions (%) 73 (83) 69 (73) 167 (73) 161 (70) 161 (87) 153 (82) 
Terminal ileum 54 49 39 41 39 41 
Ascending colon 9 9 44 41 44 41 
Transverse colon 4 2 39 38 39 38 
Desc/sigmoid colon 6 9 39 33 39 33 
Rectum 0 0 6 8 - - 
       
Exclusions (%) 15 (17) 26 (27) 63 (27) 68 (30) 25 (13) 34 (18) 
Outside DCE 3 7 42 40 12 13 
Failed DCE 
registration 
7 7 1 1 1 1 
Fecal residue 3 1 6 6 2 2 
Poor distension 0 2 6 6 3 3 
Artefacts 0 2 0 1 0 1 
Failed segmentation 2 7 8 14 7 14 
* All segments which could be evaluated by the radiologist and endoscopist. 
 
  
 Table 3 Correlations between MRI activity scores and CDEIS and 
interobserver agreement in the active segments of the full prospective cohort. 
  Observer 1 
(n=73) 
Observer 2 
(n=69) 
Interobserver agreement 
(n=56) 
MRI features r p-Value r p-Value ICC (95% CI) 
VIGOR score 0.58 <0.001 0.59 <0.001 0.81 (0.56–0.91) 
Subjective score 0.39 0.001 0.51 <0.001 0.44 (0.21–0.63) 
MaRIA 0.40 0.001 0.43 <0.001 0.44 (0.21–0.63) 
London score 0.38 0.001 0.45 <0.001 0.47 (0.24–0.65) 
CDMI 0.34 0.003 0.48 <0.001 0.59 (0.40–0.74) 
CDMI=Crohn's Disease MRI Index; MaRIA=Magnetic Resonance Index of Activity; 
MRI=Magnetic Resonance Imaging; VIGOR=Virtual Gastrointestinal Tract 
 
  
 Table 4  
Interobserver agreement for segmental scores of the 50-patient subset in 
active segments and all segments. Original ICC values are shown for both 
groups, while the non-parametric ICC is shown for all segments to account for 
the skewed distribution in this dataset. 
 
  Active (n=43) All (n=146) 
MRI features ICC (95% CI) ICC (95% CI) Non-parametric ICC 
(Rothery) 
VIGOR score 0.70 (0.51-0.82) 0.87 (0.83-0.91) 0.89 
Subjective score 0.44 (0.16-0.65) 0.77 (0.69-0.83) 0.53 
MaRIA 0.45 (0.18-0.66) 0.77 (0.69-0.83) 0.33 
London score 0.44 (0.16-0.65) 0.81 (0.75-0.86) 0.53 
CDMI 0.55 (0.30-0.73) 0.86 (0.81-0.90) 0.56 
 
MaRIA=Magnetic Resonance Index of Activity; MRI=Magnetic Resonance Imaging; 
VIGOR=Virtual Gastrointestinal Tract 
 
 
  
 Table 5  
Diagnostic accuracy for segmental MRI activity scores for detection of active 
disease (CDEIS≥3) 
  Observer 1 Observer 2 
  Sensitivity Specificity PPV NPV Accuracy Sensitivity Specificity PPV NPV Accuracy 
VIGOR score 76% 84% 63% 90% 81% 
  
74% 82% 58% 90% 80% 
Subjective 
score 
78% 67% 47% 89% 70% 
  
74% 82% 58% 90% 80% 
MaRIA 67% 86% 64% 88% 81% 
  
64% 91% 71% 88% 84% 
London score 60% 96% 84% 87% 86% 
  
57% 94% 77% 86% 84% 
CDMI 60% 92% 73% 86% 83% 
  
62% 91% 72% 87% 83% 
 
CDMI=Crohn's Disease MRI Index; MaRIA=Magnetic Resonance Index of Activity; PPV=Positive predictive value; 
NPV=Negative predictive value; VIGOR=Virtual Gastrointestinal Tract 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
